跳至主要内容
临床试验/IRCT20191228045924N7
IRCT20191228045924N7尚未招募2 期

Investigating the additional effect of methylene blue to empagliflozin on nephropathy in patients with type II diabetes

Mashhad University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
25 years 至 65 years(—)
性别
All

入选标准

  • Individuals diagnosed with type 2 diabetes between the ages of 25 and 65 are eligible for inclusion in the study.
  • Patients with a Glomerular Filtration Rate (GFR) greater than 25 and less than 90
  • Absence of liver insufficiency or active liver disease
  • Absence of active infection and sepsis.
  • Exclusion of professional athletes and individuals who have not engaged in intense physical exercise in the 9 days leading up to the sample collection.
  • Patients not currently undergoing treatment with insulin.
  • Patients with no history of polycystic kidney disease.
  • Absence of acute kidney failure due to causes other than diabetes, such as infection.
  • No history of cardiovascular diseases
  • No history of uncontrolled high blood pressure.
  • Absence of cancer or any other endocrine diseases.
  • Not having Glucose 6-phosphate dehydrogenase (G6PD) deficiency

排除标准

  • Patient's non-consent for continued cooperation.
  • Absence of cancer or any other endocrine diseases.

研究者

相似试验